Project Grant R01CA292043
- This Cooperative Agreement, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), provides $315,066 in funding to The Regents of the University of California, San Francisco (UCSF) from September 1, 2025 to August 31, 2028. The project aims to validate, translate, and clinically implement a gene expression biomarker to predict outcomes and radiotherapy responses for meningioma, a common type of brain tumor. The research will focus on improving risk...
- The National Cancer Institute (NCI) has awarded a $572,490 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The project, titled "PILLAR: Multi-Modal Imaging AI Models for Breast Cancer Risk", aims to develop an AI-powered tool to predict breast cancer risk using longitudinal data from mammograms, tomosynthesis, and MRI scans. The goal is to create more accurate cancer risk...
- This $382,449 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports research to develop and validate advanced dual-nuclei magnetic resonance imaging (MRI) techniques, including proton-based diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, to non-invasively differentiate between recurrent brain metastasis (RBM) and radiation necrosis (RN) in patients with brain metastases undergoing stereotactic...
- This Project Grant award of $162,756.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to advance understanding of chromosomal instability and radiation sensitivity in meningioma, the most common primary brain tumor. The key objectives are to: 1) Validate a transcriptomic biomarker to predict meningioma outcomes and identify patients most likely to benefit from radiation therapy; 2) Utilize novel models to define how chromosomal instability drives...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $655,306 to The Regents of the University of California, San Francisco (UCSF) to develop and evaluate a therapeutic strategy that combines a brain-penetrant glyoxalase 1 (GLO1) inhibitor with radiation for the treatment of isocitrate dehydrogenase-mutant (IDHm) gliomas, one of the deadliest forms of brain cancer. The project aims to mechanistically validate reactive metabolite...
- This Project Grant award, totaling $102,984, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The award supports research by The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, to perform spatio-temporal analyses of the entire brain-metastatic arc, from single-cell interaction with the blood-brain-barrier to fully developed brain metastases. The research will...
- This Project Grant award of $1,594,419.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research by The Regents of the University of California, San Francisco (UCSF) on "Radiopathomic Mapping of Tumor Burden for Personalized Management of IDH-Mutant Glioma." The research aims to develop innovative diagnostic and treatment approaches for a specific type of brain cancer through advanced biomedical investigations. This...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979 to The Regents of the University of California, San Francisco (UCSF) to develop an integrated metabolic therapy and imaging strategy for diffuse midline gliomas (DMGs), a type of malignant brain tumor in children. The key objectives are to: Investigate how the H3K27M mutation that drives DMG tumorigenesis affects tumor cell metabolism and the tumor microenvironment. Determine...
- This Federal Project Grant award for $236,777.00 was provided by the Defense Health Agency to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). The funding supports RAPID HIGH RESOLUTION METABOLIC IMAGING FOR IMPROVED MANAGEMENT OF PATIENTS WITH GLIOMA, a research project aimed at developing advanced imaging techniques to better manage patients with glioma, a type of brain cancer. The award term runs...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $204,295 to the University of Alabama at Birmingham to integrate advanced molecular imaging of HER2 expression and vascularity to assess treatment response to radiation in HER2+ breast-to-brain metastasis. The overarching goal is to noninvasively quantify the spatial delivery of the HER2-targeted therapy trastuzumab into brain lesions prior to radiation and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $729,587.00 to The Regents of the University of California, San Francisco (UCSF) to develop and validate a personalized, voxel-wise prediction model of brain metastases risk using multi-parametric MRI imaging. The goal is to enable more targeted and tailored whole-brain radiation therapy (WBRT) that minimizes radiation exposure to healthy brain tissue, particularly in non-small cell lung cancer patients at high risk of brain metastases. The project will integrate population-based, anatomical, vascular, and patient-specific data to create a predictive model of brain metastases risk, with the intent of reducing cognitive impairment associated with current WBRT approaches. The award period runs from August 2025 through July 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $729.6k | 8/20/25 |